Biotech entity
Of the tracked stories, 3 of 3 also mention AstraZeneca, the most common co-covered peer. The clearest coverage concentration is pharma: 2 of 3 stories, with the rest divided among 1 other category. The 7.7 average consequence score is above the beat benchmark of 6.2 in the same window.
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention AstraZeneca, the most common co-covered peer. The clearest coverage concentration is pharma: 2 of 3 stories, with the rest divided among 1 other category. The 7.7 average consequence score is above the beat benchmark of 6.2 in the same window. That works out to roughly 0.1 stories per week across a 161-day span. They are less corroborated than the beat average, carrying 3 original sources each against 3.7 for the same window. Pascal Soriot appears in 3 tracked Biotech stories published from February 24, 2026 through August 3, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 607 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pascal Soriot. Shared-story counts are live from our verified record — not editorial picks.
The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Source: eadt.co.uk · chardandilminsternews.co.uk
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
AstraZeneca CEO Pascal Soriot's total compensation for 2025 reached £17.7 million, driven by significant performance-linked bonuses. The payout reinforces Soriot's position as one of the highest-paid executives in the FTSE 100 as the company pursues an ambitious $80 billion revenue target by 2030.
Pascal Soriot is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
